Clinical Trials Directory

Trials / Withdrawn

WithdrawnNCT00445757

Stereotactic Radiation Therapy in Treating Patients With Kidney Tumors

Evaluation of a Radio-Surgical Approach for the Treatment of Kidney Tumors

Status
Withdrawn
Phase
Phase 1
Study type
Interventional
Enrollment
0 (actual)
Sponsor
Case Comprehensive Cancer Center · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

RATIONALE: Stereotactic radiation therapy may be able to send x-rays directly to the tumor and cause less damage to normal tissue. Giving stereotactic radiation therapy before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. PURPOSE: This phase I trial is studying the side effects and best dose of stereotactic radiation therapy in treating patients with kidney tumors.

Detailed description

OBJECTIVES: Primary * Determine the maximum tolerated dose of radiation in patients undergoing stereotactic radiotherapy for renal tumors. * Determine radiotherapy-associated toxicity in these patients. Secondary * Determine preoperative pathologic response to this regimen in these patients. OUTLINE: This is a dose-escalation study of radiotherapy. * Radiotherapy: Patients undergo stereotactic radiotherapy to 1 tumor. Cohorts of 4-8 patients receive escalating doses of radiotherapy twice daily for 2 days until the maximum tolerated dose (MTD) or upper limit is reached. The MTD is defined as the dose preceding that at which at least 2 of 4 or 3 of 8 patients experience dose-limiting toxicity (DLT). DLT is assessed at 4 and 8 weeks after radiotherapy. * Surgery: Two months after completion of radiotherapy, patients undergo preoperative assessment of tumor response followed by partial nephrectomy. After completion of study therapy, patients are followed periodically for at least 2 years. PROJECTED ACCRUAL: A total of 20 patients will be accrued for this study.

Conditions

Interventions

TypeNameDescription
PROCEDUREconventional surgeryTwo months after completion of radiotherapy, patients undergo preoperative assessment of tumor response followed by partial nephrectomy.
RADIATIONstereotactic radiosurgeryPatients undergo stereotactic radiotherapy to 1 tumor. Cohorts of 4-8 patients receive escalating doses of radiotherapy twice daily for 2 days until the maximum tolerated dose (MTD) or upper limit is reached.

Timeline

Start date
2007-01-01
Primary completion
2010-03-01
Completion
2010-03-01
First posted
2007-03-09
Last updated
2012-03-20

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT00445757. Inclusion in this directory is not an endorsement.

Stereotactic Radiation Therapy in Treating Patients With Kidney Tumors (NCT00445757) · Clinical Trials Directory